Combining escitalopram and cognitive-behavioural therapy for social anxiety disorder: randomised controlled fMRI trial

Affiliations

¹ Malin Gingnell, MD, PhD, Andreas Frick, PhD, Jonas Engman, MSc, Iman Alaie, MSc, Johannes Björkstrand, MSc, Department of Psychology, Uppsala University, Uppsala, Sweden; Vanda Faria, PhD, Department of Psychology, Uppsala University, Uppsala, Sweden, and Center for Pain and the Brain, Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Per Carlbring, PhD, Department of Psychology, Stockholm University, Stockholm, Sweden; Gerhard Andersson, PhD, Department of Behavioural Sciences and Learning, Psychology, Linköping University, Linköping, and Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Margareta Reis, PhD, Division of Drug Research/Clinical Pharmacology, Department of Health Sciences, Linköping University, Linköping, Sweden; Elna-Marie Larsson, MD, PhD, Department of Surgical Sciences/Radiology, Uppsala University, Uppsala, Sweden; Kurt Wahlstedt, MD, PhD, Department of Psychology, Uppsala University, Uppsala, Sweden; Mats Fredrikson, DMSc, PhD, Department of Psychology, Uppsala University, Uppsala, and Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Tomas Furmark, PhD, Department of Psychology, Uppsala University, Uppsala, Sweden malin.gingnell@psyk.uu.se.
² Malin Gingnell, MD, PhD, Andreas Frick, PhD, Jonas Engman, MSc, Iman Alaie, MSc, Johannes Björkstrand, MSc, Department of Psychology, Uppsala University, Uppsala, Sweden; Vanda Faria, PhD, Department of Psychology, Uppsala University, Uppsala, Sweden, and Center for Pain and the Brain, Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Per Carlbring, PhD, Department of Psychology, Stockholm University, Stockholm, Sweden; Gerhard Andersson, PhD, Department of Behavioural Sciences and Learning, Psychology, Linköping University, Linköping, and Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Margareta Reis, PhD, Division of Drug Research/Clinical Pharmacology, Department of Health Sciences, Linköping University, Linköping, Sweden; Elna-Marie Larsson, MD, PhD, Department of Surgical Sciences/Radiology, Uppsala University, Uppsala, Sweden; Kurt Wahlstedt, MD, PhD, Department of Psychology, Uppsala University, Uppsala, Sweden; Mats Fredrikson, DMSc, PhD, Department of Psychology, Uppsala University, Uppsala, and Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Tomas Furmark, PhD, Department of Psychology, Uppsala University, Uppsala, Sweden.

PMID: 27340112
DOI: 10.1192/bjp.bp.115.175794

Randomized Controlled Trial

Combining escitalopram and cognitive-behavioural therapy for social anxiety disorder: randomised controlled fMRI trial

Malin Gingnell et al. Br J Psychiatry. 2016 Sep.

. 2016 Sep;209(3):229-35.

doi: 10.1192/bjp.bp.115.175794. Epub 2016 Jun 23.

Affiliations

¹ Malin Gingnell, MD, PhD, Andreas Frick, PhD, Jonas Engman, MSc, Iman Alaie, MSc, Johannes Björkstrand, MSc, Department of Psychology, Uppsala University, Uppsala, Sweden; Vanda Faria, PhD, Department of Psychology, Uppsala University, Uppsala, Sweden, and Center for Pain and the Brain, Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Per Carlbring, PhD, Department of Psychology, Stockholm University, Stockholm, Sweden; Gerhard Andersson, PhD, Department of Behavioural Sciences and Learning, Psychology, Linköping University, Linköping, and Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Margareta Reis, PhD, Division of Drug Research/Clinical Pharmacology, Department of Health Sciences, Linköping University, Linköping, Sweden; Elna-Marie Larsson, MD, PhD, Department of Surgical Sciences/Radiology, Uppsala University, Uppsala, Sweden; Kurt Wahlstedt, MD, PhD, Department of Psychology, Uppsala University, Uppsala, Sweden; Mats Fredrikson, DMSc, PhD, Department of Psychology, Uppsala University, Uppsala, and Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Tomas Furmark, PhD, Department of Psychology, Uppsala University, Uppsala, Sweden malin.gingnell@psyk.uu.se.
² Malin Gingnell, MD, PhD, Andreas Frick, PhD, Jonas Engman, MSc, Iman Alaie, MSc, Johannes Björkstrand, MSc, Department of Psychology, Uppsala University, Uppsala, Sweden; Vanda Faria, PhD, Department of Psychology, Uppsala University, Uppsala, Sweden, and Center for Pain and the Brain, Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Per Carlbring, PhD, Department of Psychology, Stockholm University, Stockholm, Sweden; Gerhard Andersson, PhD, Department of Behavioural Sciences and Learning, Psychology, Linköping University, Linköping, and Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Margareta Reis, PhD, Division of Drug Research/Clinical Pharmacology, Department of Health Sciences, Linköping University, Linköping, Sweden; Elna-Marie Larsson, MD, PhD, Department of Surgical Sciences/Radiology, Uppsala University, Uppsala, Sweden; Kurt Wahlstedt, MD, PhD, Department of Psychology, Uppsala University, Uppsala, Sweden; Mats Fredrikson, DMSc, PhD, Department of Psychology, Uppsala University, Uppsala, and Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Tomas Furmark, PhD, Department of Psychology, Uppsala University, Uppsala, Sweden.

PMID: 27340112
DOI: 10.1192/bjp.bp.115.175794

Abstract

Background: Selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioural therapy (CBT) are often used concomitantly to treat social anxiety disorder (SAD), but few studies have examined the effect of this combination.

Aims: To evaluate whether adding escitalopram to internet-delivered CBT (ICBT) improves clinical outcome and alters brain reactivity and connectivity in SAD.

Method: Double-blind, randomised, placebo-controlled neuroimaging trial of ICBT combined either with escitalopram (n = 24) or placebo (n = 24), including a 15-month clinical follow-up (trial registration: ISRCTN24929928).

Results: Escitalopram+ICBT, relative to placebo+ICBT, resulted in significantly more clinical responders, larger reductions in anticipatory speech state anxiety at post-treatment and larger reductions in social anxiety symptom severity at 15-month follow-up and at a trend-level (P = 0.09) at post-treatment. Right amygdala reactivity to emotional faces also decreased more in the escitalopram+ICBT combination relative to placebo+ICBT, and in treatment responders relative to non-responders.

Conclusions: Adding escitalopram improves the outcome of ICBT for SAD and decreased amygdala reactivity is important for anxiolytic treatment response.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Cambridge University Press
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Combining escitalopram and cognitive-behavioural therapy for social anxiety disorder: randomised controlled fMRI trial

Affiliations

Combining escitalopram and cognitive-behavioural therapy for social anxiety disorder: randomised controlled fMRI trial

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical